Brief: Sana Biotechnology Says Goal To File IND For SC451 In 2024

Sana Biotechnology

12/04/2023 21:22

April 12 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY ANNOUNCES PRECLINICAL DATA PUBLISHED IN
SCIENCE TRANSLATIONAL MEDICINE SHOWING ITS HYPOIMMUNE PANCREATIC
ISLET CELLS EVADED ALLOGENEIC AND AUTOIMMUNE REJECTION AND
CONTROLLED TYPE 1 DIABETES IN PRECLINICAL MODEL
    * SANA BIOTECHNOLOGY INC - GOAL TO FILE IND FOR SC451 IN
2024
    * SANA BIOTECHNOLOGY INC - HYPOIMMUNE HUMAN ISLET CELLS
NORMALIZED
GLUCOSE IN DIABETIC HUMANIZED IMMUNOCOMPETENT MOUSE MODEL

Source text for Eikon:  ID:nGNX9q8xCY 
Further company coverage:  SANA.O 

 ((Reuters.Brief@thomsonreuters.com;))